{"id":"NCT04740931","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion","officialTitle":"A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-02","primaryCompletion":"2022-08-09","completion":"2023-07-12","firstPosted":"2021-02-05","resultsPosted":"2024-01-18","lastUpdate":"2024-08-06"},"enrollment":729,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Edema","Central Retinal Vein Occlusion","Hemiretinal Vein Occlusion"],"interventions":[{"type":"DRUG","name":"Faricimab","otherNames":["VABYSMOÂ®","faricimab-svoa","RG7716","RO6867461"]},{"type":"DRUG","name":"Aflibercept","otherNames":["Eylea"]},{"type":"PROCEDURE","name":"Sham Procedure","otherNames":[]}],"arms":[{"label":"Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)","type":"EXPERIMENTAL"},{"label":"Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals until Week 24, followed by a double-masked period of study without active control to evaluate faricimab administered according to a personalized treatment interval (PTI) dosing regimen in patients with macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).","primaryOutcome":{"measure":"Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24","timeFrame":"From Baseline through Week 24","effectByArm":[{"arm":"Arm A: Faricimab Q4W (Part 1)","deltaMin":16.9,"sd":null},{"arm":"Arm B: Aflibercept Q4W (Part 1)","deltaMin":17.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.6715"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":194,"countries":["United States","Argentina","Australia","Austria","Brazil","China","Czechia","France","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Poland","Portugal","Russia","Singapore","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["40107501","38280653"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":365},"commonTop":["COVID-19","Intraocular pressure increased","Hypertension","Conjunctival haemorrhage","Vitreous detachment"]}}